Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

NCT03136055 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)

Interventions

DRUG: Pembrolizumab
DRUG: Irinotecan
DRUG: Paclitaxel

Sponsor

University of California, San Francisco

Collaborators

[object Object]